Physician profile
Neah Kim Ling
NPI 1659539260
$2,065.15
in general payments reported to CMS, 2019-2025
15 companies · $987 in 2025
The $987 reported for 2025 was more than what 91% of Occupational Health (Nurse Practitioner) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $965 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016 · Education: $48.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.47 |
| Education | $48.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $295.05 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $243.77 | 2024 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $227.15 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $173.68 | 2024 | Fanapt |
| Janssen Pharmaceuticals, INC | $136.98 | 2025 | Invega Sustenna |
| Agios Pharmaceuticals, INC. | $126.30 | 2025 | Pyrukynd |
| Madrigal Pharmaceuticals | $124.76 | 2024 | Rezdiffra |
| Eisai INC. | $124.01 | 2025 | |
| Viatris Specialty LLC | $123.71 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $120.07 | 2025 | |
| Cequr Corporation | $117.11 | 2025 | Cequr Simplicity |
| Novo Nordisk INC | $113.00 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $104.52 | 2024 | Uzedy, Austedo Xr |
| Lundbeck LLC | $17.78 | 2024 | Rexulti |
| Indivior INC. | $17.26 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neah Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.